Biothera Pharmaceuticals Revenue

Biotechnology Research • Eagan, Minnesota, United States • 51-100 Employees

Biothera Pharmaceuticals revenue & valuation

Annual revenue	$15,000,000
Revenue per employee	$289,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$48,000,000
Total funding	$13,600,000

Key Contacts at Biothera Pharmaceuticals

Dario Herrera Murgueitio

Director Latinamerica Sales & Marketing

Nancy Herbeck

Director Of Investor Relations

Joyce Nelson

Director Of Qa

Quanren He

Director Pharmacology & Toxicology

Company overview

Headquarters	3388 Mike Collins Drive, Suite A, Eagan, MN 55121, US
Phone number	+16516730400
Website	biothera.com
NAICS	541714
SIC	873
Keywords	Oncology, Biology, Immuno-Oncology, Clinical Development, Translational Research, Immunology, Pharmaceutical Development, Cancer Immunotherapy
Founded	1997
Employees	51-100
Socials

Biothera Pharmaceuticals Email Formats

Biothera Pharmaceuticals uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 48.2% of the time.

Format	Example	Percentage
{first name}.{last name}@company.com	john.doe@company.com	48.2%
{first name initial}{last name}@company.com	{first name initial}doe@company.com	24.1%
{first name}@company.com	john@company.com	12.4%
{last name}.{first name}@company.com	doe.john@company.com	8.9%
{first name}{last name}@company.com	johndoe@company.com	6.4%

About Biothera Pharmaceuticals

Biothera Pharmaceuticals is a privately held, clinical stage immuno-oncology company developing our proprietary immunotherapy, Imprime PGG, in combination with immune checkpoint inhibitors, or CPIs, for multiple cancer indications. Imprime PGG is a biologic innate immune modulator that activates the immune system and coordinates anti-cancer immune responses that result in increased activation of cancer-specific T cells. Preclinical studies demonstrate that Imprime PGG can enhance the efficacy of anti-cancer immune responses in combination with CPI, tumor-targeting and anti-angiogenic antibodies. The Company has clinical research agreements with Merck, Genentech and AstraZeneca to evaluate Imprime PGG in combination with CPIs in multiple cancer indications, including metastatic triple negative breast cancer, head and neck cancer and colorectal cancer. Imprime PGG has shown strong evidence of tolerability in clinical trials with more than 500 subjects, including over 400 cancer patients. For more information, visit us at www.biothera.com.

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Entry

Director

Manager

Employees by Department

Biothera Pharmaceuticals has 22 employees across 9 departments.

Departments

Number of employees

Funding Data

Explore Biothera Pharmaceuticals's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2018-04-15	1	$13,600,000

Funding Insights

$13,600,000

Total funding amount

$13,600,000

Most recent funding amount

Number of funding rounds

Frequently asked questions

Biothera Pharmaceuticals is located in Eagan, Minnesota, US.

You can reach Biothera Pharmaceuticals at +16516730400.

Biothera Pharmaceuticals generates an estimated annual revenue of $15,000,000. This revenue figure reflects the company's market position and business performance in its industry.

Biothera Pharmaceuticals has an estimated valuation of $48,000,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Biothera Pharmaceuticals was founded in 1997, making it 29 years old. The company has established itself as a significant player in its industry over this time.

Biothera Pharmaceuticals has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

Biothera Pharmaceuticals has raised a total of $13,600,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.